This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.
Abstract Details
Activity Number:
|
256
|
Type:
|
Contributed
|
Date/Time:
|
Monday, August 2, 2010 : 2:00 PM to 3:50 PM
|
Sponsor:
|
Biopharmaceutical Section
|
Abstract - #309132 |
Title:
|
Comparisons of Methods in Phase I Dose-Escalation Clinical Trial Designs
|
Author(s):
|
Liping Huang*+
|
Companies:
|
Bayer HealthCare Pharmaceuticals
|
Address:
|
340 Changebridge Rd, Montville, NJ, 07045, USA
|
Keywords:
|
Maximum Tolerated Dose ;
Continual Reassessment Method ;
3+3 design ;
Dose Finding ;
Phase I ;
clinical trial
|
Abstract:
|
The goal of dose-finding for phase I oncology trials is the determination of the maximum tolerated dose (MTD). The standard method to find the MTD is the so-called '3+3' design. Many new methods have been proposed which hope to estimate the true MTD more precisely than '3+3' design while using less patients. Among them, the continual reassessment method (CRM) has gained popularity since it was proposed. In this presentation, we will compare '3+3' design and its modification with CRM and its modification by simulation.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2010 program
|
2010 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.